For investors, Exxon offers exposure to oil and gas prices, a substantial and reliableDividend, and one of the strongest balance sheets in the industry. Its scale, low-cost productionAssetsand disciplinedCapitalallocation have made it a cornerstone holding for income and value investors alike.

Nitish Kishor | 08 June 2026

News

Incyte Just Paid $1.25 Billion for a Single Antibody, Here's Why VGA039 Could Be Worth 10x That in Peak Revenue

Atlantic International Down 14% Despite EPS Improving 83%, The Financial Services Company Being Sold for Reasons the Fundamentals Don't Explain

The FDA Just Accepted Alvotech's Entyvio Biosimilar for Review, Here's Why This $7 Billion Drug Market Is About to Get Significantly Cheaper

100% of Type 1 Diabetes Patients Achieved Complete Insulin Independence With This Drug, Here's the Transplant Result That Could Change Everything

Lyell Just Solved CAR-T Therapy's Biggest Gut Toxicity Problem, Here's Why This Protocol Change Opens the Door to a Pivotal Trial

Galmed Pharmaceuticals Just Acquired a Device That Solves Colorectal Surgery's Most Feared Complication, Here's the Strategic Pivot That Could Transform This Biotech

Chip Stock Recovery and Iran-Israel Ceasefire: What Monday's Market Rebound Signals for Investors

Why Corning (NYSE: GLW) Fiber Optics Stock Surged 7% on Amazon's Multibillion-Dollar AI Data Center Deal

Walmart (NYSE:WMT) Stock: How E-commerce and Advertising Are Reinventing a $946 Billion Retail Giant

Exxon Mobil (NYSE:XOM) Stock: How the Energy Giant Powers the S&P 500 With Oil, Guyana and Dividends

Latest News

CoreWeave (NASDAQ:CRWV), Astera Labs (NASDAQ:ALAB) Jump as Nasdaq 100 Adds Five New Stocks

Intel (NASDAQ: INTC) Receives Rare Double Upgrade From BofA as Agentic AI Reshapes CPU Demand Landscape

SpaceX IPO (NASDAQ: SPCX) Creates Public Valuation Benchmark That Reshapes Pricing Across Entire Space Sector

Caribou Biosciences (NASDAQ: CRBU) CB-011 Multiple Myeloma Data Shows 92% ORR and 91% MRD-Negative Rate in Phase 1

Caribou Biosciences (NASDAQ: CRBU) CAR-T Platform Posts 82% ORR in Phase 1 Lymphoma Trial, BofA Reaffirms Buy

Aditxt (NASDAQ: ADTX) $150M Ignite Proteomics Spin-Off Plan Triggers Institutional Activity and Insider Exits